Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
0 citing papers in PubMed, 17 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
Retraction · 2024-01-22Concerns/Issues about Image · Duplication of/in Image · Investigation by Journal/Publisher · Objections by Author(s) · Unreliable Results and/or Conclusions ·
Nabil A AlhakamyDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-3826-1519
Mohammed W Al-RabiaDepartment of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz Universit, Jeddah 21589, Saudi Arabia.
Shadab MdDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-9343-1066
Alaa SirwiDepartment of Natural Products and Alternative, Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-7823-1210
Selwan Saud KhayatDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Sahar Saad AlOtaibiDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Raghad Abkar HakamiDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Hadeel Al SadounDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Basmah Medhat EldakhakhnyDepartment of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-6962-5848
Wesam H AbdulaalDepartment of Biochemistry, Faculty of Science, Cancer and Mutagenesis Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-2510-1946
Hibah M AldawsariDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-9067-8565
Shaimaa M Badr-EldinDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Mahmoud A ElfakyDepartment of Natural Products and Alternative, Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-3931-9353
King Abdulaziz University · SACairo University · EG
Funding
King Abdulaziz University RG-16-166-41
6 · The paper itself
Abstract
Luliconazole is a new topical imidazole antifungal drug for the treatment of skin infections. It has low solubility and poor skin penetration which limits its therapeutic applications. In order to improve its therapeutic efficacy, spanlastics nanoformulation was developed and optimized using a combined mixture-process variable design (CMPV). The optimized formulation was converted into a hydrogel formula to enhance skin penetration and increase the efficacy in experimental cutaneous
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Development and Optimization of Luliconazole Spanlastics to Augment the Antifungal Activity against · full record | Socratic